| 0.893 | 0.001 | 0.893 | Phospholipase C inhibitor | | |
| 0.74 | 0.006 | 0.74 | Antithrombotic | | |
| 0.721 | 0.005 | 0.721 | Platelet aggregation inhibitor | | |
| 0.719 | 0.004 | 0.719 | Psychostimulant | | |
| 0.684 | 0.003 | 0.684 | Phospholipase A2 inhibitor | | |
| 0.678 | 0.001 | 0.678 | Sphingomyelinase inhibitor | | |
| 0.658 | 0.012 | 0.658 | Cholesterol antagonist | | |
| 0.608 | 0.002 | 0.608 | Vanilloid 1 agonist | | |
| 0.624 | 0.044 | 0.624 | Apoptosis agonist | | |
| 0.589 | 0.014 | 0.589 | Spasmolytic | | |
| 0.577 | 0.019 | 0.577 | Immunostimulant | | |
| 0.562 | 0.009 | 0.562 | Angiogenesis stimulant | | |
| 0.549 | 0.021 | 0.549 | Vasodilator, peripheral | | |
| 0.527 | 0.004 | 0.527 | Platelet activating factor antagonist | | |
| 0.529 | 0.012 | 0.529 | DNA damaging | | |
| 0.514 | 0.007 | 0.514 | Anesthetic general | | |
| 0.498 | 0.012 | 0.498 | Vasodilator | | |
| 0.485 | 0.006 | 0.485 | Cholinergic | | |
| 0.502 | 0.033 | 0.502 | Immunosuppressant | | |
| 0.466 | 0.003 | 0.466 | Vanilloid agonist | | |
| 0.475 | 0.015 | 0.475 | Hypolipemic | | |
| 0.473 | 0.019 | 0.473 | Vasodilator, coronary | | |
| 0.476 | 0.048 | 0.476 | Antibacterial | | |
| 0.42 | 0.007 | 0.42 | Alkylator | | |
| 0.5 | 0.088 | 0.5 | Antiinflammatory | | |
| 0.456 | 0.08 | 0.456 | Caspase 9 stimulant | | |
| 0.411 | 0.041 | 0.411 | Immunomodulator | | |
| 0.375 | 0.007 | 0.375 | Butyrylcholinesterase inhibitor | | |
| 0.372 | 0.029 | 0.372 | Amyloid beta aggregation inhibitor | | |
| 0.354 | 0.038 | 0.354 | Antiamyloidogenic | | |
| 0.33 | 0.014 | 0.33 | Bone formation stimulant | | |
| 0.314 | 0.005 | 0.314 | Telomerase inhibitor | | |
| 0.305 | 0.014 | 0.305 | Interleukin 6 antagonist | | |
| 0.323 | 0.037 | 0.323 | DNA synthesis inhibitor | | |
| 0.29 | 0.007 | 0.29 | Adenylate kinase inhibitor | | |
| 0.287 | 0.015 | 0.287 | Acetylcholinesterase inhibitor | | |
| 0.335 | 0.063 | 0.335 | Apoptosis antagonist | | |
| 0.272 | 0.002 | 0.272 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | | |
| 0.274 | 0.006 | 0.274 | Toll-Like receptor 2 antagonist | | |
| 0.287 | 0.031 | 0.287 | Non-steroidal antiinflammatory agent | | |
| 0.265 | 0.015 | 0.265 | DNA polymerase I inhibitor | | |
| 0.248 | 0.007 | 0.248 | Sphingosine 1-phosphate receptor 2 agonist | | |
| 0.245 | 0.007 | 0.245 | Antimetabolite | | |
| 0.231 | 0.004 | 0.231 | Acyl-CoA dehydrogenase inhibitor | | |
| 0.229 | 0.004 | 0.229 | Toll-Like receptor 4 antagonist | | |
| 0.276 | 0.061 | 0.276 | Platelet antagonist | | |
| 0.218 | 0.004 | 0.218 | Acetylcholine M3 receptor agonist | | |
| 0.209 | 0.005 | 0.209 | Interferon agonist | | |
| 0.232 | 0.03 | 0.232 | Acetylcholine M1 receptor antagonist | | |
| 0.226 | 0.025 | 0.226 | Anesthetic local | | |
| 0.227 | 0.033 | 0.227 | Protein kinase stimulant | | |
| 0.218 | 0.025 | 0.218 | Toll-Like receptor antagonist | | |
| 0.203 | 0.01 | 0.203 | Sphingosine 1-phosphate receptor 5 antagonist | | |
| 0.199 | 0.008 | 0.199 | Sphingosine 1-phosphate receptor 2 antagonist | | |
| 0.24 | 0.056 | 0.24 | RNA-directed DNA polymerase inhibitor | | |
| 0.208 | 0.026 | 0.208 | Arachidonic acid antagonist | | |
| 0.185 | 0.006 | 0.185 | Anabolic | | |
| 0.203 | 0.025 | 0.203 | Adenylate cyclase inhibitor | | |
| 0.216 | 0.04 | 0.216 | Cytidine deaminase inhibitor | | |
| 0.178 | 0.015 | 0.178 | Sphingosine 1-phosphate receptor 4 antagonist | | |
| 0.176 | 0.014 | 0.176 | Phosphofructokinase-1 inhibitor | | |
| 0.18 | 0.018 | 0.18 | GABA C receptor antagonist | | |
| 0.246 | 0.085 | 0.246 | Cardiotonic | | |
| 0.174 | 0.018 | 0.174 | DNA directed RNA polymerase inhibitor | | |
| 0.162 | 0.007 | 0.162 | Sphingosine 1-phosphate receptor 4 agonist | | |
| 0.272 | 0.121 | 0.272 | Calcium channel activator | | |
| 0.155 | 0.004 | 0.155 | Sphingosine 1-phosphate receptor 3 agonist | | |
| 0.154 | 0.004 | 0.154 | Lysophosphatidic acid 2 receptor antagonist | | |
| 0.163 | 0.018 | 0.163 | Folate antagonist | | |
| 0.143 | 0.004 | 0.143 | Cholesterol esterase inhibitor | | |
| 0.168 | 0.037 | 0.168 | Adenylate cyclase stimulant | | |
| 0.133 | 0.003 | 0.133 | Geranyltranstransferase inhibitor | | |
| 0.167 | 0.038 | 0.167 | Aldehyde dehydrogenase inhibitor | | |
| 0.193 | 0.069 | 0.193 | Hepatoprotectant | | |
| 0.143 | 0.022 | 0.143 | Triose-phosphate isomerase inhibitor | | |
| 0.122 | 0.005 | 0.122 | Acetylcholine M2 receptor agonist | | |
| 0.118 | 0.004 | 0.118 | Lysophosphatidic acid 3 receptor antagonist | | |
| 0.155 | 0.042 | 0.155 | Cholesterol synthesis inhibitor | | |
| 0.164 | 0.052 | 0.164 | Cell wall synthesis inhibitor | | |
| 0.155 | 0.05 | 0.155 | Cholinergic antagonist | | |
| 0.105 | 0.002 | 0.105 | Lysophosphatidic acid receptor 1 agonist | | |
| 0.137 | 0.034 | 0.137 | UDP-glucose 4-epimerase inhibitor | | |
| 0.105 | 0.008 | 0.105 | Sphingosine 1-phosphate receptor 5 agonist | | |
| 0.251 | 0.153 | 0.251 | GABA C receptor rho-3 antagonist | | |
| 0.137 | 0.041 | 0.137 | TRPA1 agonist | | |
| 0.172 | 0.077 | 0.172 | Succinate dehydrogenase inhibitor | | |
| 0.109 | 0.014 | 0.109 | Ornithine carbamoyltransferase inhibitor | | |
| 0.146 | 0.052 | 0.146 | Ca2+-transporting ATPase inhibitor | | |
| 0.127 | 0.034 | 0.127 | Acetylcholine agonist | | |
| 0.097 | 0.005 | 0.097 | Retinoid X receptor agonist | | |
| 0.12 | 0.028 | 0.12 | NADH dehydrogenase inhibitor | | |
| 0.1 | 0.008 | 0.1 | Sphingosine 1-phosphate receptor 3 antagonist | | |
| 0.104 | 0.012 | 0.104 | Phospholipase D inhibitor | | |
| 0.155 | 0.065 | 0.155 | Lipid peroxidase inhibitor | | |
| 0.108 | 0.019 | 0.108 | Ribonucleotide reductase inhibitor | | |
| 0.107 | 0.018 | 0.107 | Ribonucleoside-diphosphate reductase inhibitor | | |
| 0.092 | 0.006 | 0.092 | Glucose-6-phosphate isomerase inhibitor | | |
| 0.089 | 0.003 | 0.089 | Urotensin II agonist | | |
| 0.125 | 0.041 | 0.125 | Acetylcholine release stimulant | | |
| 0.087 | 0.004 | 0.087 | Carnitine palmitoyltransferase inhibitor | | |
| 0.084 | 0.002 | 0.084 | Toll-Like receptor 4 agonist | | |
| 0.238 | 0.159 | 0.238 | Toll-Like receptor agonist | | |
| 0.083 | 0.005 | 0.083 | Sphingosine 1-phosphate receptor 1 agonist | | |
| 0.08 | 0.004 | 0.08 | Carnitine palmitoyltransferase 1 inhibitor | | |
| 0.107 | 0.031 | 0.107 | Glutathione S-transferase inhibitor | | |
| 0.172 | 0.099 | 0.172 | DNA methylase inhibitor | | |
| 0.167 | 0.093 | 0.167 | P-glycoprotein inhibitor | | |
| 0.082 | 0.008 | 0.082 | Sphingosine 1-phosphate receptor agonist | | |
| 0.074 | 0.002 | 0.074 | Lysophosphatidic acid receptor 3 agonist | | |
| 0.097 | 0.025 | 0.097 | Potassium channel large-conductance Ca-activated activator | | |
| 0.13 | 0.058 | 0.13 | Acetylcholine muscarinic antagonist | | |
| 0.076 | 0.005 | 0.076 | Purinergic P2Y2 antagonist | | |
| 0.092 | 0.023 | 0.092 | Carbamoyl phosphate synthetase inhibitor | | |
| 0.098 | 0.03 | 0.098 | Thioredoxin reductase inhibitor | | |
| 0.072 | 0.007 | 0.072 | Membrane dipeptidase inhibitor | | |
| 0.097 | 0.032 | 0.097 | Glutamate dehydrogenase inhibitor | | |
| 0.105 | 0.041 | 0.105 | Aminoacyl-tRNA synthetase inhibitor | | |
| 0.065 | 0.002 | 0.065 | Vanilloid 2 agonist | | |
| 0.083 | 0.021 | 0.083 | Glutamate (mGluR6) antagonist | | |
| 0.191 | 0.129 | 0.191 | 5 Hydroxytryptamine release stimulant | | |
| 0.094 | 0.033 | 0.094 | Acetylcholine M4 receptor antagonist | | |
| 0.166 | 0.111 | 0.166 | Anticonvulsant | | |
| 0.069 | 0.016 | 0.069 | Purinergic P2Y antagonist | | |
| 0.073 | 0.02 | 0.073 | Sphingosine kinase 2 inhibitor | | |
| 0.054 | 0.004 | 0.054 | Adenosine uptake inhibitor | | |
| 0.099 | 0.049 | 0.099 | Calcium antagonist | | |
| 0.073 | 0.024 | 0.073 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | | |
| 0.082 | 0.033 | 0.082 | Acetylcholine M5 receptor agonist | | |
| 0.056 | 0.008 | 0.056 | Purinergic P2X agonist | | |
| 0.072 | 0.025 | 0.072 | Potassium channel (Ca-activated) blocker | | |
| 0.074 | 0.028 | 0.074 | Argininosuccinate synthase inhibitor | | |
| 0.095 | 0.05 | 0.095 | Ornithine decarboxylase inhibitor | | |
| 0.068 | 0.024 | 0.068 | Autotaxin inhibitor | | |
| 0.051 | 0.007 | 0.051 | Carnitine palmitoyltransferase 1A inhibitor | | |
| 0.145 | 0.101 | 0.145 | Antipruritic | | |
| 0.087 | 0.044 | 0.087 | Na+ K+ transporting ATPase inhibitor | | |
| 0.047 | 0.004 | 0.047 | Lysophosphatidic acid 1 receptor antagonist | | |
| 0.116 | 0.074 | 0.116 | Acetylcholine antagonist | | |
| 0.059 | 0.018 | 0.059 | Thymidylate synthase inhibitor | | |
| 0.051 | 0.013 | 0.051 | Phosphoglycerate kinase inhibitor | | |
| 0.086 | 0.049 | 0.086 | Acetylcholine nicotinic antagonist | | |
| 0.069 | 0.033 | 0.069 | Biliverdin reductase inhibitor | | |
| 0.061 | 0.026 | 0.061 | Alpha-mannosidase inhibitor | | |
| 0.085 | 0.05 | 0.085 | Glycine receptor antagonist | | |
| 0.077 | 0.046 | 0.077 | Lipase inhibitor | | |
| 0.055 | 0.026 | 0.055 | Nicotinic receptor alpha4 subunit antagonist | | |
| 0.078 | 0.051 | 0.078 | Keratolytic | | |
| 0.06 | 0.034 | 0.06 | Acetylcholine muscarinic agonist | | |
| 0.094 | 0.071 | 0.094 | GABA C receptor rho-1 antagonist | | |
| 0.04 | 0.017 | 0.04 | Ceramide glucosyltransferase inhibitor | | |
| 0.111 | 0.088 | 0.111 | Cathepsin H inhibitor | | |
| 0.032 | 0.01 | 0.032 | 1,3-Beta-glucan synthase inhibitor | | |
| 0.038 | 0.016 | 0.038 | Acetylcholine M4 receptor agonist | | |
| 0.038 | 0.017 | 0.038 | Growth factor receptor-bound protein 2 antagonist | | |
| 0.191 | 0.17 | 0.191 | 5 Hydroxytryptamine uptake stimulant | | |
| 0.055 | 0.034 | 0.055 | Acetyl-CoA transferase inhibitor | | |
| 0.049 | 0.031 | 0.049 | Cytokine production stimulant | | |
| 0.091 | 0.073 | 0.091 | Phosphodiesterase 6D inhibitor | | |
| 0.075 | 0.057 | 0.075 | Sphingosine 1-phosphate receptor antagonist | | |
| 0.04 | 0.023 | 0.04 | Nicotinic receptor beta4 subunit antagonist | | |
| 0.032 | 0.016 | 0.032 | Hypoxanthine phosphoribosyltransferase inhibitor | | |
| 0.018 | 0.002 | 0.018 | Mannitol 2-dehydrogenase inhibitor | | |
| 0.193 | 0.177 | 0.193 | Angiogenesis inhibitor | | |
| 0.059 | 0.043 | 0.059 | Acetylcholine M5 receptor antagonist | | |
| 0.024 | 0.008 | 0.024 | Toll-Like receptor 8 agonist | | |
| 0.055 | 0.04 | 0.055 | Sphingosine 1-phosphate receptor 1 antagonist | | |
| 0.035 | 0.02 | 0.035 | Squalene synthetase inhibitor | | |
| 0.021 | 0.006 | 0.021 | Purinergic receptor agonist | | |
| 0.021 | 0.006 | 0.021 | Purinergic P2 agonist | | |
| 0.08 | 0.066 | 0.08 | Estrogen-related receptor beta agonist | | |
| 0.085 | 0.07 | 0.085 | Potassium channel (Ca-activated) activator | | |
| 0.021 | 0.006 | 0.021 | Purinergic P2Y1 agonist | | |
| 0.154 | 0.141 | 0.154 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | | |
| 0.038 | 0.027 | 0.038 | Vanilloid 3 antagonist | | |
| 0.164 | 0.154 | 0.164 | Interleukin agonist | | |
| 0.02 | 0.009 | 0.02 | Methylmalonyl-CoA mutase inhibitor | | |
| 0.015 | 0.006 | 0.015 | Purinergic P2Y agonist | | |
| 0.067 | 0.059 | 0.067 | Porphobilinogen synthase inhibitor | | |
| 0.105 | 0.096 | 0.105 | Cyclooxygenase 3 inhibitor | | |
| 0.056 | 0.048 | 0.056 | Sphingosine kinase inhibitor | | |
| 0.042 | 0.037 | 0.042 | Mannosidase inhibitor | | |
| 0.016 | 0.011 | 0.016 | Purinergic P2Y1 antagonist | | |
| 0.038 | 0.035 | 0.038 | Acetylcholine M1 receptor agonist | | |
| 0.066 | 0.062 | 0.066 | Carbonic anhydrase XIII inhibitor | | |
| 0.038 | 0.035 | 0.038 | Sphingosine kinase 1 inhibitor | | |
| 0.042 | 0.04 | 0.042 | Peroxisome proliferator-activated receptor alpha agonist | | |
| 0.081 | 0.08 | 0.081 | Aminopeptidase B inhibitor | | |